By the Industry News Team
In our mid-February sector analysis, we discussed the “valuation tightrope” facing ASX Health Care stocks. Today, February 19, that rope has snapped for some, while others have ascended to new heights.
While the broader ASX 200 hit a historic milestone of 9,100 points today, the Health Care sector (XHJ) is telling a tale of two markets: a massive recovery for diagnostic giants and a brutal recalibration for some of the index’s largest heavyweights.
1. Sonic Healthcare: The Sector’s “Superman” Today
Sonic Healthcare (SHL) is the undisputed headline-maker of the day. Its shares erupted, closing up nearly 10% (and hitting an intraday peak of 14%) following a stellar half-year result.
-
The Numbers: Revenue jumped 17% to $5.45 billion, with statutory NPAT rising 11% to $262 million.
-
The Driver: While the U.S. market remained flat, Sonic’s performance in Germany and the UK was exceptional. Investors were particularly heartened by the 5% organic growth in Australian pathology, which outperformed major competitors.
-
Dividends: Management maintained its progressive policy, bumping the interim dividend up to 45 cents per share.
2. CSL & Cochlear: The Giants Stumble
It has been a difficult week for the “Big Two” of Aussie healthcare. The sector is grappling with high expectations that have proven difficult to meet.
-
-
CSL Limited (CSL): Trading at what some analysts call an “eight-year low” relative to its growth profile, CSL remains under pressure. Following its February 11 report—which saw an 81% decline in NPAT due to restructuring costs—the stock has struggled to find a floor, currently hovering around the $154 mark.
-
Cochlear (COH): After reporting on February 13, the hearing implant leader has faced a sustained sell-off. While it reached a milestone with the Nucleus Nexa system, a 9% dip in underlying profit and margin contraction to 73% led to a 25% price correction over the last week. Today, it remains near its 52-week low.
-
3. Health Insurance: Medibank Under Pressure
While our Energy update showed profit surges, the health insurance space is feeling the squeeze of rising claims.
-
Medibank Private (MPL): Shares tumbled over 6% today. Despite the government approving a 5.1% premium increase for April, Medibank’s underlying profit of $298 million missed consensus estimates. Rising surgical costs and higher-than-expected policyholder utilization have narrowed the margins that investors were counting on.
4. Biotech Watch: Telix’s Path to Recovery
Telix Pharmaceuticals (TLX) provided a glimmer of hope for the biotech sub-sector. After a rough start to 2026, the stock saw a minor uptick today following the announcement that it has submitted a European marketing authorization application for its brain cancer imaging agent, TLX101-Px. With no commercial alternatives currently available, analysts are watching closely to see if this marks the bottom of the recent sell-off.
Market Outlook
The Health Care sector is currently undergoing a “vibe shift.” The era of buying any medical stock at any price is over. Investors are now ruthlessly punishing any earnings misses (as seen with Cochlear and Medibank) while aggressively rewarding operational efficiency and organic growth (as seen with Sonic).
The Bottom Line: The “defensive” reputation of healthcare is being tested. While the sector offers long-term structural tailwinds, the current reporting season proves that valuation discipline is now the primary driver of share price performance.
